Ligand Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $39.9K
- Price
- $0.002
- % Change (Daily % change from the live per-ticker quote feed.)
- -55.56%
- Volume
- 10.2K
About
Ligand Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise, primarily engaged in sourcing and advancing innovative technologies. These technologies are instrumental in assisting other pharmaceutical businesses with the identification and progression of new therapeutic solutions. The company's portfolio includes medications such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. Ronald M. Evans founded the organization in 1987, and its principal corporate offices are located in San Diego, California.
Quick stats
Shares outstanding19.9M
Computed float18.9M
Float / shares94.7%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000886163
Websitehttp://www.ligand.com
AI Summary
AI-generated1/35
minorbullishpartnership
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Ligand Pharmaceuticals entered a financing agreement with AvenCell Therapeutics worth up to $47 million to advance AvenCell's allogeneic CAR-T pipeline.
Ligand committed up to $41 million for a mid single-digit to low double-digit royalty on worldwide net sales of AvenCell assets, funded in four tranches tied to clinical milestones, plus up to $6 million in a Series C round.
The deal adds exposure to AvenCell's lead programs AVC-201 (relapsed/refractory AML, Phase 1b expansion) and AVC-203 (B-cell malignancies, Phase 1a), expanding Ligand's royalty portfolio of more than 200 assets.
Red flags
- royalty tied to pre-commercial, early-stage clinical assets (Ph1b/Ph1a) with uncertain approval and sales prospects
- most funding contingent on future milestones and financing conditions